Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127656831 | 12765683 | 1 | I | 201410 | 20160628 | 20160921 | 20160921 | PER | US-JNJFOC-20160702022 | JANSSEN | 56.87 | YR | A | M | Y | 0.00000 | 20160921 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127656831 | 12765683 | 1 | PS | XARELTO | RIVAROXABAN | 1 | Oral | Y | N | 22406 | 10 | MG | TABLET | QD | |||||
| 127656831 | 12765683 | 2 | SS | HEPARIN | HEPARIN SODIUM | 1 | Subcutaneous | Y | 0 | INJECTION | |||||||||
| 127656831 | 12765683 | 3 | SS | COUMADIN | WARFARIN SODIUM | 1 | Unknown | U | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127656831 | 12765683 | 1 | Pulmonary embolism |
| 127656831 | 12765683 | 2 | Thrombosis prophylaxis |
| 127656831 | 12765683 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127656831 | 12765683 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127656831 | 12765683 | Haematuria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127656831 | 12765683 | 1 | 20140815 | 20141013 | 0 |